Several previous studies also reported that CVD risk was high in both smokers and non-smokers with clustering of metabolic risk factors [17]. Therefore, it is important to elucidate the attribution of obesity, metabolic syndrome, and smoking to CVD mortality in Asia, where obesity is still less common compared with Western countries.

The purpose of this report is to examine excess CVD deaths and population attributable fractions on CVD deaths by the combination of smoking and metabolic syndrome (or obesity) in a 15-year cohort study of randomly selected representative Japanese samples from the National Survey on Circulatory Disorders of Japan.

Methods

Participants and follow-up

Cohort studies of the National Survey on Circulatory Disorders of Japan comprise the National Integrated Project for Prospective Observation of Non-communicable Disease and Its Trends in the Aged (NIPPON DATA). Baseline surveys for the cohort of this report were performed in 1990 (NIPPON DATA90) [18,19]. We analyzed the 15-year follow-up data of NIPPON DATA90 in this report.

A total of 8383 men and women aged ≥ 30 years from 300 randomly selected districts were participated in the survey in 1990. The baseline surveys were carried out at local public health centers. The participation rate in the baseline survey was 76.5%. The present study was for 7329 participants aged 30 to 70 years at baseline. From these participants, we excluded 379 participants who had a history of coronary heart disease or stroke (n = 249) or who had missing information in the baseline survey (n = 130). Thus, 6650 participants (2752 men and 3898 women) were eligible for the analyses.

NIPPON DATA90 has completed follow-up surveys until 2005. We used the National Vital Statistics data to indentify the cause of death. The underlying causes of death in the National Vital Statistics were coded according to the 9th International Classification of Disease (ICD-9) until the end of 1994 and according to the 10th International Classification of Disease (ICD-10) from 1995. Deaths from any CVD were identified by ICD-9 codes (393-459) and ICD-10 codes (I00-I99). The details of the classification are described elsewhere [18,19]. The Institutional Review Board of Shiga University of Medical Science (NO.12-18, 2000) approved the study.

Biochemical and physical examinations

Public health nurses obtained data including smoking habit, as well as current health status and medical history. Public health nurses asked all participants about current smoking status (current smoking, past smoking and never-smoking), the number of cigarettes per day and the duration of smoking. Smoking habit was categorized into non-smoker, past smoker and current smoker. Drinking habit was categorized into non-drinker, past drinker, occasional drinker and daily drinker. Body mass index was calculated as weight divided by height squared (kg/m^2).

Non-fasting blood samples were obtained at the baseline survey. The serum was separated and centrifuged soon after blood coagulation. Plasma samples were collected in siliconized tubes containing sodium fluoride and shipped to one laboratory (SRL, Tokyo, Japan) for blood measurements. Plasma glucose was measured enzymatically. Serum triglycerides and total cholesterol were also measured enzymatically, and high density lipoprotein (HDL) cholesterol was measured after heparin-calcium precipitation [20].

We defined metabolic risk factors using the Japanese criteria of the metabolic syndrome [21,22] as follow: obesity as body mass index ≥ 25 kg/m^2; high blood pressure: BP ≥ 130/85 mm Hg or on treatment for hypertension; high blood glucose: serum glucose ≥ 110 mg/dl or on treatment for diabetes; dyslipidemia: serum triglyceride ≥ 150 mg/dl, HDL cholesterol < 40 mg/dl or on treatment for dyslipidemia. We defined the metabolic syndrome as having obesity (defined as body mass index ≥ 25 kg/m^2) and two or more other metabolic risk factors; the definition was modified from the Japanese criteria [22] where the presence of obesity is essential. We defined metabolic risk factors clustering as having two or more metabolic risk factors.

Statistical analysis

Multivariate-adjusted hazard ratios (HR) of all CVD deaths for each component of metabolic risk factors including BMI, systolic BP (SBP), triglyceride, glucose, HDL cholesterol were calculated using Cox proportional hazards models. Multivariate-adjusted HR for all CVD deaths according to metabolic risk factors and smoking categories were calculated using Cox proportional hazards models adjusted for age and drinking. Non-smokers without metabolic syndrome or obesity were set as the reference group.

Population attributable fractions (PAF) for CVD deaths due to the combination of smoking and metabolic syndrome (or obesity) were calculated based on hazard ratios assessed by proportional hazards models [23,24]. PAF was estimated as $pd \times (HR-1)/HR$ where pd is the proportion of death cases arising from the each categories. All analyses were performed by SAS 9.1 (Statistical Analysis System, Cary, NC).

Results

Baseline characteristics are shown in Table 1. Mean age at baseline was 49.9 years in men and 49.0 years in women. Mean body mass index was 23.1 kg/m^2 in men and 22.9 kg/m^2 in women. Smoking rate was 58.0% in men and

Table 1: Baseline characteristics of study population. NIPPON DATA90, men and women aged 30 to 70 years in 1990.

	Men		Women	
Number (N)	2752		3898	
Age (year)	49.9	±11.2	49.0	±11.3
BMI (kg/m²)	23.1	±3.0	22.9	±3.3
SBP (mmHg)	136.2	±19.5	131.3	±19.9
DBP (mmHg)	83.8	±11.7	79.4	±11.8
Total cholesterol (mg/dl)	199.6	±36.6	205.5	±38.0
HDL cholesterol (mg/dl)	50.4	±15.0	57.5	±14.9
Triglyceride (mg/dl)	151.8	±108.8	119.1	±79.8
Blood glucose (mg/dl)	102.0	±33.4	101.1	±28.9
Drinking				
Non drinker	921	33.5%	3572	91.6%
Ex-drinker	141	5.1%	39	1.0%
Current drinker	1690	61.4%	287	7.4%
Smoking				
Never smoker	556	20.2%	3431	88.0%
Ex-smoker	601	21.8%	94	2.4%
Current smoker	1595	58.0%	373	9.6%
Obesity	689	25.1%	912	23.4%
High blood pressure	1840	66.9%	2119	54.4%
High blood glucose	578	21.0%	829	21.3%
Dyslipidemia	1280	46.5%	1094	28.1%

Values are number, %, or mean ± SD.
High blood pressure, BP ≥ 130/85 mmHg or on treatment of hypertension; high blood glucose, blood glucose≥ 110 mg/dl or on treatment of diabetes; dyslipidemia as triglyceride≥ 150 mg/dl or high density lipoprotein < 40 mg/dl or on treatment of dyslipidemia. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high density lipoprotein.

Table 2: Adjusted HR for 1 standard deviation increasing in the continuous variables and sex, smoking and drinking habits for mortality from cardiovascular diseases.

	Adjusted hazard ration (95%CI)		
Current -smoker	3.45	(2.12	-5.60)
Past-smoker	2.04	(1.11	-3.75)
Body mass index (1 SD increasing)	0.99	(0.83	-1.18)
Systolic blood pressure (1 SD increasing)	1.32	(1.13	-1.54)
Triglyceride (1 SD increasing)*	0.85	(0.69	-1.04)
High density lipoprotein cholesterol (1 SD increasing)	0.93	(0.76	-1.11)
Glucose (1 SD increasing)	1.10	(1.00	-1.24)
Female	1.00	(0.61	-1.64)

This Cox model also includes age, and drinking habit.
* The variable was tested after log-transferred.

9.6% in women. The prevalence of hypertension and obesity were 66.9% and 25.1% in men and 54.4% and 23.4% in women.

During 15 years of follow-up, 87 men and 61 women died due to CVD (37 men and 22 women died due to stroke and 30 men and 8 women died due to coronary heart disease). Table 2 shows HRs of CVD death for each component of metabolic risk factors including all factors in a model, simultaneously. It showed that current smoking, past-smoking, SBP and glucose were significant risk factors of CVD mortality. Table 3 shows adjusted HRs and PAFs for CVD deaths according to the combination of obesity and smoking status. Irrespective of obesity, smoking and CVD mortality in both men and women were positively related. HRs (95% confidence interval [CI]) for non-obese smokers was 3.13 (1.33 to 7.36) in men and 4.32 (1.99 to 9.37) in women compared with non-obese, non-smokers. Estimated numbers of excess CVD deaths (and PAF component) in the non-obese smokers and obese smokers were 32.0 (36.8%), and 7.9 (9.1%) in men and 6.9 (11.3%) and 3.2 (5.2%) in women. The sum of the estimated number of excess CVD deaths (PAF) due to smoking and/or obesity was 49.3 (56.9%) in men and 15.3 (25.1%) in women.

Table 4 shows adjusted HRs and PAF components due to combination of smoking status and metabolic syndrome. Compared to non-smokers without metabolic syndrome, adjusted HRs (95% CI) for CVD deaths was higher in smokers with and without metabolic syndrome (HR 3.19 [1.13 to 9.03] and 3.47 [1.48 to 8.12] in men; 4.94 [1.52 to 16.09] and 3.63 [1.75 to 7.50] in women, respectively). PAFs for CVD mortality in smokers with and without metabolic syndrome were 7.1% and 40.9% in men and 3.9% and 11.9% in women, respectively. The sum of PAF components due to smoking and/or metabolic syndrome was 60.4% in men and 17.0% in women.

Table 5 shows adjusted HRs and PAF components due to the combination of smoking status and clustering of metabolic risk factors. Compared to non-smokers without metabolic risk factor clustering, adjusted HRs (95% CI) for CVD death in smokers with and without metabolic risk factor clustering were 5.85 (1.40 to 24.38) and 4.17 (0.98 to 17.71) for men, and 5.86 (2.41 to 14.23) and 4.56 (1.62 to 12.87) for women, respectively. PAF components for CVD mortality in non-smokers with metabolic risk factors clustering, smokers without metabolic risk factors clustering and smokers with metabolic risk factors clustering were 2.8%, 20.1% and 34.3% for men, and 18.7%, 6.4% and 10.9% for women, respectively.

Table 3: Hazard ratio and population attributable fraction for cardiovascular disease deaths according to the combination of smoking status and obesity*: NIPPON DATA90

		Number of participants	Person-years of follow-up	CVD deaths (n)	CVD mortality rate (per 1,000 person-years)	Adjusted hazard ratio (95% CI)†		Estimated excess CVD deaths (n)	PAF component for CVD deaths (%)
Men									
Non smoker	Non-obese	420	5938	6	1.01	1.00			
	Obese	136	1988	1	0.50	0.67	(0.08 -5.53)	–	–
Past smoker	Non-obese	431	6116	16	2.62	1.93	(0.75 -4.96)	7.7	8.8
	Obese	170	2414	5	2.07	1.52	(0.46 -4.99)	1.7	2.0
Smoker	Non-obese	1212	16780	47	2.80	3.13	(1.33 -7.36)	32.0	36.8
	Obese	383	5277	12	2.27	2.92	(1.09 -7.82)	7.9	9.1
Women									
Non smoker	Non-obese	2,638	37960	29	0.76	1.00			
	Obese	793	11256	17	1.51	1.34	(0.74 -2.45)	4.3	7.1
Past smoker	Non-obese	66	843	1	1.19	1.43	(0.19 -10.61)	0.3	0.5
	Obese	28	383	1	2.61	2.46	(0.33 -18.09)	0.6	1.0
Smoker	Non-obese	282	3889	9	2.31	4.32	(1.99 -9.37)	6.9	11.3
	Obese	91	1224	4	3.27	4.74	(1.66 -13.58)	3.2	5.2

*Obesity was defined as body mass index ≥ 25 kg/m^2.

†Hazard ratios were adjusted for age and drinking.

CVD, cardiovascular diseases; PAF, population attributable fraction; CI, confidence interval.

Table 4: Hazard ratio and population attributable fraction for cardiovascular disease deaths according to the combination of smoking status and metabolic syndrome: NIPPON DATA90.

	Metabolic syndrome*	Number of participants	Person-years of follow-up	CVD deaths (n)	CVD mortality rate (per 1,000 person-years)	Adjusted hazard ratio(95% CI) †		Estimated excess CVD deaths (n)	PAF component for CVD deaths (%)
Men									
Non smoker	-	480	6817	6	0.88	1.00			
	+	76	1109	1	0.90	1.32	(0.16 -10.97)	0.2	0.3
Past smoker	-	494	7036	18	2.56	2.13	(0.84 - 5.39)	9.5	11.0
	+	107	1494	3	2.01	1.49	(0.37 - 6.01)	1.0	1.1
Smoker	-	1343	18620	50	2.69	3.47	(1.48 - 8.12)	35.6	40.9
	+	252	3437	9	2.62	3.19	(1.13 - 9.03)	6.2	7.1
Women									
Non smoker	-	3,034	43585	38	0.87	1.00			
	+	397	5631	8	1.42	0.83	(0.38 - 1.78)	–	–
Past smoker	-	81	1042	1	0.96	1.06	(0.15 - 7.81)	0.05	0.1
	+	13	184	1	5.45	2.98	(0.41 -21.79)	0.6	1.1
Smoker	-	336	4627	10	2.16	3.63	(1.75 - 7.50)	7.2	11.9
	+	37	486	3	6.17	4.94	(1.52 -16.09)	2.4	3.9

*Metabolic syndrome were defined as follows: obesity (body mass index ≥ 25 kg/m²) plus any two of the following three factors: high blood pressure as blood pressure ≥ 130/85 mmHg or on treatment of hypertension, high blood glucose as blood glucose ≥ 110 mg/dl or on treatment of diabetes, dyslipidemia as triglyceride ≥ 150 mg/dl or high density lipoprotein cholesterol <40 mg/dl or on treatment of dyslipidemia.

†Hazard ratios were adjusted for age and drinking.

CVD, cardiovascular diseases; PAF, population attributable fraction; CI, confidence interval.

Table 5: Hazard ratio and population attributable fraction for cardiovascular disease deaths according to the combination of smoking status and clustering of metabolic risk factors: NIPPON DATA90.

	Clustering of metabolic risk factors*	Number of participants	Person-years of follow-up	CVD deaths (n)	CVD mortality rate (per 1,000 person-years)	Adjusted hazard ratio (95% CI) †		Estimated excess CVD deaths (n)	PAF component for CVD deaths (%)
Men									
Non smoker	0 or 1	281	4002	2	0.50	1.00			
	2 ≤	275	3924	5	1.27	1.94	(0.38 -10.00)	2.4	2.8
Past smoker	0 or 1	282	4084	7	1.71	2.41	(0.50 -11.65)	4.1	4.7
	2 ≤	319	4446	14	3.15	3.37	(0.76 -14.96)	9.8	11.3
Smoker	0 or 1	819	11465	23	2.01	4.17	(0.98 -17.71)	17.5	20.1
	2 ≤	776	10592	36	3.40	5.85	(1.40 -24.38)	29.8	34.3
Women									
Non smoker	0 or 1	2,117	30554	14	0.46	1.00			
	2 ≤	1314	18661	32	1.71	1.55	(0.82 -2.95)	11.4	18.7
Past smoker	0 or 1	54	698	0	–		--	–	–
	2 ≤	40	527	2	3.79	3.08	(0.69 -13.81)	1.4	2.2
Smoker	0 or 1	222	3098	5	1.61	4.56	(1.62 -12.87)	3.9	6.4
	2 ≤	151	2016	8	3.97	5.86	(2.41 -14.23)	6.6	10.9

*Metabolic risk factors were any of the following four factors: obesity (body mass index ≥ 25 kg/m²), high blood pressure as blood pressure ≥ 130/85 mmHg or on treatment of hypertension, high blood glucose as blood glucose ≥ 110 mg/dl or on treatment of diabetes, dyslipidemia as triglyceride ≥ 150 mg/dl or high density lipoprotein cholesterol < 40 mg/dl or on treatment of dyslipidemia.
†Hazard ratios were adjusted for age and drinking.
CVD, cardiovascular diseases; PAF, population attributable fraction; CI, confidence interval.

Discussion

The present report of a representative Japanese cohort showed that the majority of excess CVD deaths were observed in smokers without metabolic syndrome. The PAF component of CVD deaths in smokers without metabolic syndrome were 5 times higher than those in participants with metabolic syndrome in men (40.9% vs. 8.5%). The HR of CVD deaths in smokers without metabolic syndrome were also higher than non-smokers without metabolic syndrome, and it was similar to the HR in smokers with metabolic syndrome (3.47 vs. 3.19).

In Asian countries including Japan, there has been a rise in metabolic syndrome [7,25]. In these areas, prevalence of smoking has been higher than that in Western countries and smoking rates has been still increasing in younger women [14]. Previous studies have reported that obesity and smoking are risk factors for CVD [5,6,10,11]. The association of clustering of metabolic risk factors, including hyperglycemia, dyslipidemia, and hypertension, with CVD risk has also been widely reported [1,4,17,18]. Furthermore, a previous study from Japan reported that the effect of risk factor accumulation on CVD incidence was more evident among smokers than non smokers [17]. However, these previous reports did not show the attribution of the combination of smoking and metabolic syndrome (or obesity) to CVD events. To our knowledge, this is the first report showing that the majority of excess CVD deaths occurred in smokers without metabolic syndrome in a Asian population. A strength of our report is that the study was conducted in a 15-year cohort of nationwide representative Japanese samples.

In Japan, new health checkups and healthcare advice focusing on the metabolic syndrome to prevent CVD began in April 2008 through health insurance providers [7]. Our results support the necessity of intervention for people with metabolic syndrome because these people appear to be at higher CVD risk; however, PAF component in men and in women with metabolic syndrome were only 8.5% and 5.0%, respectively. On the other hand, the present study indicated that PAFs among smokers without metabolic syndrome were 40.9% in men and 11.9% in women; who are not the target population of the new health educational program in Japan. Moreover, not only PAF but also HR of smokers without metabolic syndrome was substantially higher. Thus the program might overlook a large population at an increased risk of CVD. Activities of smoking cessation for non-obese people would be still important for the prevention of CVD in Japan.

In the present study, we examined the association between each component of metabolic risk factors and CVD death. We conformed that current and past smoking, SBP and glucose were significant risk factors of CVD mortality in our study participants. Several previous reports revealed that clustering of metabolic risk factors increases CVD risk, irrespective of the presence of obesity [17,18]. When obesity was dealt with one of metabolic risk factors (not an essential factor) in the present study (Table 5), the PAF in smokers with metabolic risk factor clustering got larger in men (34.3%). However, even for smokers without metabolic risk factors clustering in the present study, PAF was 20.1% in men. This finding indicated that even if obesity is not essential for the diagnostic criteria of metabolic syndrome like the National Cholesterol Education Program (NCEP) [26], an intervention for smokers without clustering of metabolic risk factors would be also important for the prevention of CVD.

This study has several limitations. First, we used non-fasting blood samples and thus we might have misclassified several individuals with diabetes and dyslipidemia. Second, we used body mass index ≥ 25 kg/m^2 to define obesity and thus we might have misclassified individuals with abdominal obesity with higher waist circumference. However, this limitation would be ignorable because the correlation between BMI and waist circumstance is usually high enough. The cut-off point of body mass index for Japanese [21] is different from that for Asia-Pacific Region in the WHO definition (body mass index ≥ 23 kg/m^2) [27], which may underestimate the PAF in Asian people. Third, we did not adjust for socioeconomic status in this study. However, all Japanese are covered by the national health insurance program and socioeconomic status would not limit access to treatment in Japan. Fourth, in this study, we used information on smoking habit from self-reported smoking history; this may cause recall and information biases. Fifth, the numbers of participants or CVD events were not enough to analyze according to the number of cigarettes per day; therefore, we did not consider the intensity of smoking in this paper.

Conclusions

In conclusion, this long-term cohort study of representative Japanese samples indicated that CVD mortality in smokers without metabolic syndrome or without obesity was substantially high and a large proportion of excess deaths were observed in these groups. These findings suggest that intervention targeting on smokers, irrespective of the presence of metabolic syndrome (or obesity), is still important for the prevention of CVD death in relatively lean Japanese population with high smoking rate. This could apply to other Asian populations with high smoking rate but with lower prevalence of obesity compared with Western populations.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
All authors contributed to the concept, design, analysis, interpretation of data, and preparation of the manuscript. All authors read and approved the final manuscript.

Acknowledgements
The authors thank all public health centers that cooperated with our study.
List of the NIPPON DATA90 Research Group
Chairperson: Hirotsugu Ueshima (Department of Health Science, Shiga University of Medical Science, Otsu, Shiga).
Research members: Akira Okayama (The First Institute for Health Promotion and Health Care, Japan Anti-Tuberculosis Association, Tokyo), Kazunori Kodama and Fumiyoshi Kasagi (Radiation Effects Research Foundation, Hiroshima), Shigeyuki Saitoh (Department of 2nd Internal Medicine, Sapporo Medical University, Sapporo, Hokkaido), Kiyomi Sakata (Department of Hygiene and Preventive Medicine, Iwate Medical University, Morioka, Iwate), Yoshikazu Nakamura (Department of Public Health, Jichi Medical University, Shimotsuke, Tochigi), Yoshikuni Kita (Department of Health Science, Shiga University of Medical Science, Otsu, Shiga), Tomonori Okamura (Department of Preventive Cardiology, National Cardiovascular Center, Suita, Osaka), Koji Tamakoshi (Department of Public Health and Health Information Dynamics, Nagoya University Graduate School of Medicine, Nagoya, Aichi), Yasuyuki Nakamura (Cardiovascular Epidemiology, Kyoto Women's University, Kyoto), Yutaka Kiyohara (Department of Environmental Medicine, Kyushu University, Fukuoka), Yasuhiro Matsumura (Faculty of Healthcare, Kiryu University, Midori City, Gunma), Katsushi Yoshita (Project for the Naitonal Health and Nutrition Survey, National Institute of Health and Nutrition, Tokyo), Hideaki Nakagawa (Department of Epidemiology and Public Health, Kanazawa Medical University, Ishikawa), Takehito Hayakawa (Department of Hygiene and Preventive Medicine, Fukushima Medical University, Fukushima), Katsuyuki Miura (Department of Health Science, Shiga University of Medical Science, Otsu, Shiga), Toshiyuki Ojima (Department of Community Health and Preventive Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka), Nagako Okuda (Department of Health Science, Shiga University of Medical Science, Otsu, Shiga), Atsushi Hozawa (Division of Epidemiology, Department of Public Health and Forensic Medicine, Tohoku University School of Medicine, Sendai, Miyagi).
Role of Sponsor: The sponsors did not participate in the design or conduct of the study; the collection; management, analysis, and interpretation of the study; or the preparation, review, or approval of the manuscript.
Funding: This study was supported by the grant-in-aid of the Ministry of Health and Welfare under the auspices of Japanese Association for Cerebro-cardiovascular Disease Control, the Research Grant for Cardiovascular Diseases (7A-2) from the Ministry of Health, Labour and Welfare and a Health and Labour Sciences Research Grant, Japan (Comprehensive Research on Aging and Health: H11-chouju-046, H14-chouju-003, H17-chouju-012 and H19-chouju-014).

Author Details
[1]Department of Health Science, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga 520-2192, Japan, [2]Department of Public Health, Yamagata University School of Medicine, Iida Nishi 2-2-1, Yamagata, Yamagata, 990-9585, Japan, [3]Department of Preventive Cardiology, National Cardiovascular Center, Fujishirodai 5-7-1, Suita, Osaka, 565-8565, Japan, [4]The Cardiovascular Epidemiology, Kyoto Women's University, Imakumanokitahiyoshi-cho35, Kyoto, Kyoto, 605-8501, Japan, [5]Department of Hygiene and Preventive Medicine, Fukushima Medical University, Hikarigaoka1, Fukushima, Fukushima, 960-1295, Japan and [6]The First Institute for Health Promotion and Health Care, Japanese Anti-Tuberculosis Association, Misaki-cho1-3-12, Chiyoda, Tokyo, 101-061, Japan

Received: 29 September 2009 Accepted: 3 June 2010
Published: 3 June 2010

References

1. Criqui MH, Barrett-Connor E, Holdbrook MJ, Austin M, Turner JD: **Clustering of cardiovascular disease risk factors.** *Prev Med* 1980, **9**:525-33.
2. Reaven GM: **Banting lecture 1988. Role of insulin resistance in human disease.** *Diabetes* 1988, **37**:1595-607.
3. Kaplan NM: **The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension.** *Arch Intern Med* 1989, **149**:1514-20.
4. DeFronzo RA, Ferrannini E: **Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.** *Diabetes Care* 1991, **14**:173-94.
5. World Health Organization: **Obesity: preventing and managing the global epidemic. Report of a WHO consultation.** Geneva, Switzerland: World Health Organization; 2004.
6. Melanson KJ, McInnis KJ, Rippe JM, Blackburn G, Wilson PF: **Obesity and cardiovascular disease risk: research update.** *Cardiol Rev* 2001, **9**:202-7.
7. **Annual Report on Health Labour Welfare.** Tokyo Japan Ministry of Health Labour and Welfare; 2007. (in Japanese)
8. Lakier JB: **Smoking and cardiovascular disease.** *Am J Med* 1992, **93**:8S-12S.
9. Ueshima H, Choudhury SR, Okayama A, Hayakawa T, Kita Y, Kadowaki T, Okamura T, Minowa M, Iimura O: **Cigarette smoking as a risk factor for stroke death in Japan: NIPPON DATA80.** *Stroke* 2004, **35**:1836-41.
10. Higa M, Davanipour Z: **Smoking and stroke.** *Neuroepidemiology* 1991, **10**:211-22.
11. Seltzer CC: **Framingham study data and "established wisdom" about cigarette smoking and coronary heart disease.** *J Clin Epidemiol* 1989, **42**:743-50.
12. Murakami Y, Ueshima H, Okamura T, Kadowaki T, Hozawa A, Kita Y, Hayakawa T, Okayama A: **Life expectancy among Japanese of different smoking status in Japan: NIPPON DATA80.** *J Epidemiol* 2007, **17**:31-7.
13. Ueshima H, Sekikawa A, Miura K, Turin TC, Takashima N, Kita Y, Watanabe M, Kadota A, Okuda N, Kadowaki T, Nakamura Y, Okamura T: **Cardiovascular Disease and Risk Factors in Asian: A Selected Review.** *Circulation* 2008, **118**:2702-2709.
14. Brundtland GH: **The Tobacco Atlas.** Geneva Switzerland the World Health Organization; 2002.
15. Health and Welfare Statistics Association: **Journal of Health and Welfare Statistics. Tokyo Japan Health and Welfare Statistics Association.** 2007. (in Japanese)
16. Martiniuk AL, Lee CM, Lam TH, Huxley R, Suh I, Jamrozik K, Gu DF, Woodward M, Asia Pacific Cohort Studies Collaboration: **The fraction of ischaemic heart disease and stroke attributable to smoking in the WHO Western Pacific and South-East Asian regions.** *Tob Control* 2006, **15**:181-8.
17. Iso H, Sato S, Kitamura A, Imano H, Kiyama M, Yamagishi K, Cui R, Tanigawa T, Shimamoto T: **Metabolic syndrome and the risk of ischemic heart disease and stroke among Japanese men and women.** *Stroke* 2007, **38**:1744-51.
18. Kadota A, Hozawa A, Okamura T, Kadowaki T, Nakmaura K, Murakami Y, Hayakawa T, Kita Y, Okayama A, Nakamura Y, Kashiwagi A, Ueshima H: **Relationship between metabolic risk factor clustering and cardiovascular mortality stratified by high blood glucose and obesity: NIPPON DATA90, 1990-2000.** *Diabetes Care* 2007, **30**:1533-8.
19. Okamura T, Hayakawa T, Kadowaki T, Kita Y, Okayama A, Ueshima H, NIPPON DATA90 Research Group: **The inverse relationship between serum high-density lipoprotein cholesterol level and all-cause mortality in a 9.6-year follow-up study in the Japanese general population.** *Atherosclerosis* 2006, **184**:143-50.
20. Nakamura M, Sato S, Shimamoto T: **Improvement in Japanese clinical laboratory measurements of total cholesterol and HDL-cholesterol by the US Cholesterol Reference Method Laboratory Network.** *J Atheroscler Thromb* 2003, **10**:145-153.
21. Examination Committee of Criteria for 'Obesity Disease' in Japan; Japan Society for the Study of Obesity: **New criteria for 'obesity disease' in Japan.** *Circ J* 2002, **66**:987-92.
22. Committee to Evaluate Diagnostic Standards for Metabolic Syndrome: **Definition and the diagnostic standard for metabolic syndrome--Committee to Evaluate Diagnostic Standards for Metabolic Syndrome.** *Nippon Naika Gakkai Zasshi* 2005, **94**:794-809. (in Japanese)
23. Rockhill B, Newman B, Weinberg C: **Use and misuse of population attributable fractions.** *Am J Public Health* 1998, **88**:15-9.
24. Hozawa A, Okamura T, Murakami Y, Kadowaki T, Nakamura K, Hayakawa T, Kita Y, Nakamura Y, Abbott RD, Okayama A, Ueshima H: **Joint impact of smoking and hypertension on cardiovascular disease and all-cause**

mortality in Japan: NIPPON DATA80, a 19-year follow-up. *Hypertens Res* 2007, **30**:1169-75.
25. World Health Organization: **World Health Statistics 2007.** Geneva, Switzerland: World Health Organization; 2007.
26. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP): **Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).** *JAMA* 2001, **285**:2486-2497.
27. Choo V: **WHO reassesses appropriate body-mass index for Asian populations.** *Lancet* 2002, **360**:235.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2458/10/306/prepub

doi: 10.1186/1471-2458-10-306
Cite this article as: Takashima *et al.*, Population Attributable Fraction of Smoking and Metabolic Syndrome on Cardiovascular Disease Mortality in Japan: a 15-Year Follow Up of NIPPON DATA90 *BMC Public Health* 2010, **10**:306

Atherosclerosis 215 (2011) 209–213

Contents lists available at ScienceDirect

Atherosclerosis

journal homepage: www.elsevier.com/locate/atherosclerosis

Relationship of moderate metabolic risk factor clustering to cardiovascular disease mortality in non-lean Japanese: A 15-year follow-up of NIPPON DATA90

Aya Kadota[a,b,*], Katsuyuki Miura[a], Tomonori Okamura[c], Atsushi Hozawa[d], Yoshitaka Murakami[a], Akira Fujiyoshi[a], Naoyuki Takashima[a], Takehito Hayakawa[e], Yoshikuni Kita[a], Akira Okayama[f], Yasuyuki Nakamura[g], Hirotsugu Ueshima[a], for the NIPPON DATA90 Research Group[1]

[a] Department of Health Science, Shiga University of Medical Science, Otsu, Japan
[b] Department of Internal Medicine, Shiga University of Medical Science, Otsu, Japan
[c] Department of Preventive Medicine and Public Health, Keio University, Tokyo, Japan
[d] Department of Public Health, Yamagata University Graduate School of Medicine, Yamagata, Japan
[e] Department of Hygiene and Preventive Medicine, Fukushima Medical University, Fukushima, Japan
[f] The First Institute of Health Service, Japan Anti-Tuberculosis Association, Tokyo, Japan
[g] Cardiovascular Epidemiology, Kyoto Women's University, Kyoto, Japan

ARTICLE INFO

Article history:
Received 10 December 2009
Received in revised form
21 November 2010
Accepted 25 November 2010
Available online 4 December 2010

Keywords:
Metabolic risk factor
Cardiovascular disease
Mortality
Epidemiology

ABSTRACT

Objective: The individual components of metabolic syndrome are defined as levels ranging from moderate to high level as to require medication. We investigated the impact of moderate metabolic risk factor clustering on cardiovascular disease (CVD) mortality.
Methods: We followed up 6758 non-lean Japanese in randomly selected areas from all over the country who had no history of CVD for 15 years. The multivariate-adjusted hazards ratio (HR) and 95% confidence interval (CI) for CVD mortality according to the number of moderate metabolic risk factors (BMI $\geq$ 25 kg/m^2, 130/85 mmHg $\leq$ systolic/diastolic BP < 140/90 mmHg, 140 mg/dl $\leq$ casual blood glucose < 200 mg/dl, triglycerides $\geq$ 150 mg/dl and/or HDL cholesterol < 40 mg/dl [men], 50 mg/dl [women]) were estimated using the Cox proportional hazards model. The population-attributable risk fraction of moderate metabolic risk factor clustering was also estimated.
Results: During the follow-up, 282 participants died of CVD. CVD mortality tended to increase with the number of moderate metabolic risk factors. However, they were not statistically significant. The multivariate-adjusted HRs were 1.82 (95%CI: 0.89–3.73) for having any moderate metabolic risk factors and 2.87 (95%CI: 1.46–5.64) for having any medication-required metabolic risk factors, compared with participants without any moderate metabolic risk factors. The population-attributable risk fractions were 7.3% and 52.4% for any moderate and medication-required metabolic risk factors, respectively.
Conclusions: We did not find the statistically significant increase of CVD mortality for moderate metabolic risk factor clustering. Its attribution was relatively small in this Japanese population. More efforts would be required to detect and control medication-required risk factors.

1. Introduction

Metabolic syndrome is the concept of metabolic risk factor clustering, which is an appropriate target for therapeutic lifestyle changes [1–4]. Several cohort studies have revealed that metabolic syndrome is associated with an increased risk of cardiovascular disease (CVD) [5–11]. However, the individual component risk factors in the present criteria for metabolic syndrome are not graded by severity but they are defined as levels ranging from moderate to high requiring medication [12–17]. Because individual established risk factors such as hypertension or diabetes strongly and independently increase the risk of CVD [8,18,19], the risk of moderate metabolic risk factor clustering on CVD might escape detection. Individuals with established risk factors often require medication in addition to therapeutic lifestyle changes, whereas moderate risk factors can be controlled with such lifestyle changes [17]. However, the CVD risk for individuals with moderate risk factor clustering has rarely been reported.

Here we investigated the association between clustering of moderate metabolic risk factors and CVD mortality among people with normal weight or more in a 15-year follow-up of a cohort of

* Corresponding author at: Department of Health Science, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga 520-2192, Japan.
Tel.: +81 77 548 2191; fax: +81 77 543 9732.
E-mail address: ayakd@belle.shiga-med.ac.jp (A. Kadota).
[1] Members of the Research Group are listed in the Appendix.

0021-9150/$ – see front matter © 2010 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.atherosclerosis.2010.11.033

representative general Japanese, who participated in the National Survey of Circulatory Disorders of Japan in 1990.

2. Methods

2.1. Study population

NIPPON DATA (National Integrated Project for Prospective Observation of Non-communicable Disease and Its Trends in the Aged) is a cohort study of participants in the National Survey on Circulatory Disorders of Japan, which has been conducted by the Ministry of Health, Labor and Welfare of Japan. NIPPON DATA includes two cohort studies of which the baseline data were surveyed in 1980 and in 1990 (NIPPON DATA80 and NIPPON DATA90) and the details of the studies have been described [8,18–20]. Here, we investigated the data from NIPPON DATA90 because some important metabolic risk factors such as HDL cholesterol were not included in the NIPPON DATA80 baseline survey.

A total of 8384 residents (3504 men and 4880 women, aged ≥ 30 years) from 300 randomly selected districts from all over Japan participated in the baseline survey and were followed up until November, 2005. The participation rate in this survey was 76.5%. Of the 8384 participants, 1626 were excluded because of a history of coronary heart disease or stroke (n = 261), information missing at the baseline survey (n = 649), withdrawal due to incomplete residential access information (n = 255) and a low BMI (BMI < 18.5 kg/m^2) (n = 461). We excluded these lean participants because they also have a higher CVD mortality risk in Japan as well as in western studies [21,22]. The remaining 6758 participants (2828 men and 3930 women) were analyzed in this study. The Institutional Review Board of Shiga University of Medical Science (No. 12-18, 2000) approved this study.

2.2. Baseline examination

Body mass index (BMI) was calculated as weight (kg) divided by the square of height (m). Trained observers measured baseline blood pressure using a standard mercury sphygmomanometer on the right arm of seated participants. Non-fasting blood samples were obtained at the baseline survey. Serum was separated and centrifuged soon after blood coagulation. Plasma samples were collected into siliconized tubes containing sodium fluoride and shipped to a central laboratory (SRL, Tokyo) for blood measurements. Plasma glucose was measured enzymatically. Serum triglycerides (TG) and total cholesterol were also measured enzymatically and high-density lipoprotein (HDL) cholesterol was measured after heparin–calcium precipitation.

Public health nurses collected the information about smoking, alcohol consumption and medical history. We divided participants into four categories of smokers (never-smoked; ex-smoker; current smoker of <20 or ≥20 cigarettes/day) and six categories of drinking (never-drink; ex-drinker; current drinker of 1–4 and more *gou* of sake/day); 1 *gou* (180 ml) is equivalent to 23 g of alcohol.

2.3. Endpoints

We previously reported that participants who had died in each area were confirmed by computer matching with data from the National Vital Statistics database, using area, gender, date of birth and death as key codes [19,23]. The underlying causes of death in the National Vital Statistics were coded according to the 9th International Classification of Diseases (ICD-9) until 1994 and according to the 10th International Classification of Disease (ICD-10) from 1995. Details of these classifications are described elsewhere [18–20,23]. Deaths coded from 393 to 459 according to ICD-9 and from I00 to I99 according to ICD-10 were defined as CVD deaths in this study.

2.4. Definition of metabolic risk factors

Based on the modified NCEP (National Cholesterol Education Program) metabolic syndrome criteria [12], moderate metabolic risk factors were defined as follows: obesity (BMI ≥ 25 kg/m^2), moderate high blood pressure (130 ≤ systolic blood pressure [SBP] < 140 mmHg and/or 85 ≤ diastolic blood pressure [DBP] < 90 mmHg), dyslipidemia (150 mg/dl ≤ non-fasting triglycerides and/or HDL-cholesterol < 40 mg/dl for men, and <50 mg/dl for women). We also defined moderate high blood glucose (140 mg/dl ≤ non-fasting blood glucose < 200 mg/dl). Because our samples were non-fasting, post load blood glucose of ≥140 mg/dl indicated impaired glucose tolerance [24]. Furthermore, we defined medication-required metabolic risk factors as follows: high blood glucose (non-fasting blood glucose ≥ 200 mg/dl and/or medication), high blood pressure (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg and/or medication) according to the criteria of hypertension stage 1 in JNC7 (The Seventh Report of the Joint National Committee of Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) [25]. We divided the participants into five categories of metabolic risk factor condition (none, moderate metabolic risk factor [1, 2 and ≥3 factors], any medication-required metabolic risk factor). Participants with any one or more of the medication-required metabolic risk factors were categorized as "any medication-required metabolic risk factor" irrespective of the number of moderate metabolic risk factors.

2.5. Statistical analysis

Differences in the baseline characteristics of participants were examined using the analysis of variance for continuous variables and χ^2-test for dichotomized variables according to metabolic risk factors. The multivariate-adjusted hazard ratio (HR) of all CVD mortality for each group was estimated using the Cox proportional hazards model adjusted for age, sex, total cholesterol, smoking and drinking categories. Participants without metabolic risk factors were established as the reference group. Population-attributable risk fraction (PAF) for CVD deaths were estimated using the following equation: proportion of CVD death with moderate metabolic factors among total CVD death × (HR − 1)/HR [26]. All CI values were estimated at the 95% level. A P-value of <0.05 was considered statistically significant. The Statistical Package for the Social Sciences, version 11.0J (SPSS Japan, Inc., Tokyo, Japan) was used for all analysis.

3. Results

Table 1 shows the baseline characteristics of the study participants according to the categories of metabolic risk factors. The mean age of participants was higher and the proportion of women was lower among those with more advanced metabolic risk factors. The proportion of participants with any moderate metabolic risk factors was 33.6%. The total number of person-years was 94,817 and the mean follow-up period was 14.0 years. During the follow-up, 1007 participants died of all causes, 282 of all CVD, 119 of stroke and 63 of coronary heart disease.

Table 2 shows the number of deaths, adjusted HRs and 95%CIs according to metabolic risk factors. Crude HR values for CVD mortality ranged from 2.32 to 5.17 among participants with moderate metabolic risk factors. The trend was statistically significant among the four categories of moderate and the five categories up to medication-required metabolic risk factors (P for trend < 0.001). Multivariate-adjusted HRs among participants with moderate

Table 1
Baseline characteristics of 2828 men and 3930 women aged ≥30 years according to number of moderate or medication-required metabolic risk factors. NIPPON DATA90, 15-year follow-up.

Baseline characteristics	Number of moderate metabolic risk factors[a]				Any medication-required metabolic risk factors[b]
	0	1	2	3 and 4	
Number of participants	1297	1393	683	199	3186
Women (%)	69.1	58.8	56.5	45.7	54.5
Age (years)	44.0 ± 10.5	47.0 ± 11.8	50.0 ± 12.4	50.8 ± 12.8	58.6 ± 12.5
BMI (kg/m^2)	21.3 ± 1.7	22.5 ± 2.3	24.5 ± 2.8	26.9 ± 2.6	23.9 ± 3.1
Systolic blood pressure (mmHg)	115.1 ± 8.8	122.4 ± 10.4	127.7 ± 8.2	132.1 ± 4.9	151.7 ± 16.6
Diastolic blood pressure (mmHg)	71.8 ± 7.5	75.6 ± 7.7	78.1±7.4	81.2 ± 6.4	89.1 ± 10.9
Blood glucose (mg/dl)	92.6 ± 13.2	96.3 ± 15.4	100.1 ± 19.6	108.9 ± 25.2	110.3 ± 42.0
HbAlc (%)	4.69 ± 0.34	4.78 ± 0.36	4.89 ± 0.44	5.01 ± 0.52	5.13 ± 0.95
Total cholesterol (mg/dl)	193.7 ± 31.7	195.4 ± 35.8	207.8 ± 38.8	217.1 ± 37.2	210.3 ± 39.5
Triglycerides (mg/dl)	80.0 ± 28.3	123.4 ± 76.7	168.9 ± 93.2	213.9 ± 112.8	150.2 ± 103.2
HDL-cholesterol (mg/dl)	63.6 ± 12.7	52.8 ± 14.2	45.9 ± 12.1	43.2 ± 12.2	52.2 ± 15.3
Drinking					
Never-drink (%)	75.8	69.8	71.6	67.8	63.7
Ex-drinker (%)	1.9	2.2	2.6	1.5	3.7
Current drinker (%)	22.3	28.0	25.8	30.7	32.6
Smoking					
Never-smoked (%)	68.8	61.3	57.8	47.7	57.9
Ex-smoker (%)	9.0	8.4	9.4	10.6	14.0
Current smoker (%)	22.2	30.3	32.8	41.7	28.1
Moderate or medication-required metabolic risk factors (%)					
Obesity	0	12.1	45.1	91.0	33.1
Triglycerides/HDL cholesterol	0	48.8	82.9	97.0	51.4
Blood glucose	0	1.5	5.7	17.1	11.1
Blood pressure	0	37.5	66.3	99.0	97.3

BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high density lipoprotein.

[a] Moderate metabolic risk factors were defined as follows: moderate high blood glucose (140 mg/dl ≤ non-fasting blood glucose < 200 mg/dl), moderate high blood pressure (130 ≤ SBP < 140 mmHg and/or 85 ≤ DBP < 90 mmHg), moderate dyslipidemia (150 mg/dl ≤ non-fasting triglycerides and/or (HDL-cholesterol < 40 mg/dl in men or HDL-cholesterol < 50 mg/dl in women), obesity (BMI ≥ 25 kg/m^2).

[b] Medication-required metabolic risk factors were defined as follows: high blood glucose (non-fasting blood glucose ≥ 200 mg/dl and/or on medication), high blood pressure (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg and/or on medication).

metabolic risk factors ranged from 1.61 to 2.26 with a statistically significant increase. The trend in the multivariate-adjusted model was statistically significant ($P < 0.001$) among the five categories of metabolic risk factors, although it did not reach statistical significance among the four categories of moderate metabolic risk factors. These relationships were similar in gender-specific analyses.

Table 3 shows multivariate adjusted HRs and 95%CIs according to the three categories of metabolic risk factors (none, any moderate metabolic risk factors and any medication-required metabolic risk factors). Crude HR was 2.98 times higher in participants with any moderate metabolic risk factor than in those with none, and multivariate-adjusted HR was 1.82. PAFs calculated by multivariate adjusted HRs were 7.3% and 52.4% for any moderate and medication-required metabolic risk factors, respectively.

4. Discussion

This 15-year follow-up of a representative Japanese cohort did not find the statistically significant increase of CVD mortality for the moderate metabolic risk factor clustering. In addition, PAF was relatively small (7.3%) in people with any moderate factors compared with those with any medication-required factors (52.4%). To the best of our knowledge, this would be the first report to clarify the CVD risk of moderate metabolic risk factor clustering,

Table 2
Multivariate adjusted hazard ratios of cardiovascular deaths according to number of moderate or medication-required metabolic risk factors. NIPPON DATA90, 15-year follow-up.

	Number of moderate metabolic risk factors[a]				Any medication-required metabolic risk factors[b]
	0	1	2	3 and 4	
Number of participants	1297	1393	683	199	3186
Person-years	19,082	20,148	9835	2883	42,869
Cardiovascular deaths	9	22	17	7	227
Mortality per 1000 person-years	0.47	1.09	1.73	2.43	5.30
Crude HR (95%CI)	1	2.32 (1.07–5.05)	3.68 (1.64–8.26)	5.17 (1.93–13.88)	11.46 (5.89–22.30)
Age and sex adjusted HR (95%CI)	1	1.58 (0.73–3.43)	1.92 (0.85–4.31)	2.04 (0.76–5.49)	2.70 (1.38–5.30)
Multivariate adjusted HR[c] (95%CI)	1	1.61 (0.74–3.50)	2.02 (0.90–4.54)	2.26 (0.84–6.10)	2.88 (1.47–5.65)

BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high density lipoprotein; HR, hazard ratio; CI, confidence interval.

[a] Moderate metabolic factors were defined as follows: moderate high blood glucose (140 mg/dl ≤ non-fasting blood glucose < 200 mg/dl), moderate high blood pressure (130 ≤ SBP < 140 mmHg and/or 85 ≤ DBP < 90 mmHg), moderate dyslipidemia (150 mg/dl ≤ non-fasting triglycerides and/or (HDL-cholesterol < 40 mg/dl in men or HDL-cholesterol < 50 mg/dl in women), obesity (BMI ≥ 25 kg/m^2).

[b] Medication-required metabolic factors were defined as follows: high blood glucose (non-fasting blood glucose ≥ 200 mg/dl and/or on medication), high blood pressure (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg and/or on medication).

[c] Multivariate hazard ratios were estimated by Cox proportional hazard model adjusted for sex, age, total cholesterol, smoking habits and drinking habits.

Table 3
Multivariate adjusted hazard ratios of cardiovascular deaths for having any moderate or medication-required metabolic risk factors. NIPPON DATA90, 15-year follow-up.

	None	Any moderate metabolic risk factors[a]	Any medication-required metabolic risk factors[b]	*P* for trend
Number of participants	1297	2275	3186	
Person-years	19,082	32,866	428,69	
Cardiovascular deaths	9	46	227	
Mortality per 1000 person-years	0.47	1.40	5.30	
Crude HR (95%CI)	1	2.98 (1.46–6.09)	11.46 (5.88–22.30)	<0.001
Age and sex adjusted HR (95%CI)	1	1.75 (0.86–3.58)	2.70 (1.38–5.29)	<0.001
Mutivariate adjusted HR[c] (95%CI)	1	1.82 (0.89–3.73)	2.87 (1.46–5.64)	<0.001

BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high density lipoprotein; HR, hazard ratio; CI, confidence interval.

[a] Moderate metabolic factors were defined as follows: moderate high blood glucose (140 mg/dl < non-fasting blood glucose < 200 mg/dl), moderate high blood pressure (130 ≤ SBP < 140 mmHg and/or 85 ≤ DBP < 90 mmHg), moderate dyslipidemia (150 mg/dl ≤ non-fasting triglycerides and/or (HDL-cholesterol < 40 mg/dl in men or HDL-cholesterol < 50 mg/dl in women), obesity (BMI ≥ 25 kg/m^2).

[b] Medication-required metabolic factors were defined as follows: high blood glucose (non-fasting blood glucose ≥ 200 mg/dl and/or on medication), high blood pressure (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg and/or on medication).

[c] Multivariate hazard ratios were estimated by Cox proportional hazard model adjusted for sex, age, total cholesterol, smoking habits and drinking habits.

especially in Asia, where stroke is the predominant cause of CVD mortality.

The influence of metabolic syndrome on CVD risk has been reported [5–11]. McNeil et al. used NCEP criteria and found that the adjusted HR for coronary heart disease incidence was 1.46 for men and 2.05 for women, and that for ischemic stroke incidence was 1.42 for men and 1.96 for women in the Atherosclerosis Risk in Communities Study [5]. Katzmarzyk et al. investigated the relationship between metabolic syndrome diagnosed by NCEP criteria and CVD mortality among 19,223 men in the USA and found that the adjusted HR was 1.23 [6]. Iso et al. reported in a study using the modified NCEP criteria found that the adjusted HR for the incidence of ischemic heart disease was 2.4 and that of ischemic stroke was 1.8 among 9087 Japanese in five communities [9]. Ninomiya et al. found using modified NCEP criteria that the adjusted HR of CVD incidence among 2452 Japanese in Hisayama Study was 1.86 for men and 1.70 for women [10]. All of these previous studies demonstrate a CVD risk associated with metabolic syndrome irrespective of the severity of the individual component. For example, high blood pressure is defined according to the NCEP criteria as ≥130/85 mmHg, a value that covers a range of blood pressure from high-normal to severe hypertension. However, the CVD risk for individuals with moderate risk factor clustering, which is not usually treated by medication, has rarely been reported.

In the present study, moderate metabolic risk factor clustering tended to increase CVD mortality, however, they were not statistically significant. Several epidemiological studies have revealed that the CVD risk factors included in the criteria for metabolic syndrome are incrementally associated with CVD risk and do not have any threshold [27,28]. Therefore, combined moderate metabolic risk factors might increase the CVD risk. Further studies are required to clarify the relationship of moderate metabolic risk factor clustering and CVD risk.

In the present study, the prevalence of participants with any moderate metabolic risk factor was 33.6% and the PAF of moderate metabolic risk factors on CVD mortality was 7.3%. The impact of moderate metabolic factors on a population should be assessed by estimating population-attributable risk fraction of moderate metabolic factors, which has been seldom reported yet. Vasan et al. investigated the relative contribution of borderline (suboptimal but below current treatment thresholds) and elevated risk factors among US population using five traditional vascular risk factors (blood pressure, low-density lipoprotein cholesterol level, high-density lipoprotein cholesterol, glucose tolerance and smoking status) [29]. They found that the prevalence of the isolated borderline risk factors decreased with age and ranged from 19% to 32.6% in men and from 28.6% to 55.2% in women. They also indicated that isolated borderline risk factors without elevated risk factors accounted for only about 10% of hard CHD events. Although different risk factors and different ranges were applied in their study, their results would be comparable to our results. Our smaller PAF in people with moderate metabolic risk factors would be partly due to smaller range of moderate BP elevation (SBP/DBP 130–139/85–89 mmHg) in the criteria of metabolic syndrome.

The present study indicated that HR of CVD deaths was near 3-folds among participants with any medication-required metabolic risk factor and their PAF was over 50%. Previous studies have shown that almost 80% of patients with coronary heart disease had at least one major risk factor [30,31]. Our findings among participants with any medication-required metabolic risk factors were comparable with these results and emphasize the importance of focusing upon individuals with any severe risk factor to prevent CVD. The statement of the American Heart Association and National Heart, Lung and Blood Institute recommends that established risk factors such as elevated blood pressure ≥ 140/90 mmHg and elevated glucose ≥ HbA1c 7% should be medicated in addition to undergoing therapeutic lifestyle changes [17]. However, many people with any medication-required metabolic risk factor are neither yet detected nor controlled. Further efforts are required to identify and control established risk factors.

Several limitations should be noted about this study. Firstly, analysis of non-fasting blood samples and no consideration of treatment for dyslipidemia might have resulted in misclassifications of serological abnormalities. Secondly, we used BMI because information about waist circumference was unavailable. Since waist circumference might more precisely enhance the effect of obesity on CVD than BMI, we might have under- or overestimated the effect of obesity. However, BMI is closely related to waist circumference.

In conclusion, we did not find the statistically significant increase of CVD mortality for moderate metabolic risk factor clustering in a representative Japanese population. Further studies are required to clarify the relationship of moderate metabolic risk factor clustering and CVD risk. In addition, its attribution to CVD deaths was relatively small compared with having any medication-required risk factors in this Asian population. People with moderate metabolic risk factors should modify their lifestyle mainly to reduce weight, but more efforts would be required to detect and control medication-required risk factors for CVD prevention.

Conflict of interest

None.

Acknowledgements

This study was supported by the grant-in-aid of the Ministry of Health, Labor and Welfare under the auspices of Japanese Asso-

ciation for Cerebro-cardiovascular Disease Control, the Research Grant for Cardiovascular Diseases (7A-2) from the Ministry of Health, Labor and Welfare, and the Health and Labor Sciences Research Grant, Japan (Comprehensive Research on Aging and Health [H11-Chouju-046, H14-Chouju-003, H17-Chouju-012, H19-Chouju-Ippan-014] and Comprehensive Research on Life-Style Related Diseases including Cardiovascular Diseases and Diabetes Mellitus [H22-Jyunkankitou-Seisyu-Sitei-017]). We appreciate the members of the NIPPON DATA80/90 Research Group which is listed in the Appendix.

Appendix A. The NIPPON DATA80/90 Research Group

Chairperson: Hirotsugu Ueshima (Department of Health Science, Shiga University of Medical Science, Otsu, Shiga).

Co-Chairperson: Akira Okayama (The First Institute for Health Promotion and Health Care, Japan Anti-Tuberculosis Association, Tokyo) for the NIPPON DATA80, Tomonori Okamura (Department of Preventive Medicine and Public Health, Keio University, Tokyo) for the NIPPON DATA90.

Research members: Shigeyuki Saitoh (Department of 2nd Internal Medicine, Sapporo Medical University, Sapporo, Hokkaido), Kiyomi Sakata (Department of Hygiene and Preventive Medicine, Iwate Medical University, Morioka, Iwate), Atsushi Hozawa (Department of Public Health, Yamagata University Graduate School of Medicine, Yamagata), Takehito Hayakawa (Department of Hygiene and Preventive Medicine, Fukushima Medical University, Fukushima), Yosikazu Nakamura (Department of Public Health, Jichi Medical University, Shimotsuke, Tochigi), Yasuhiro Matsumura (Faculty of Healthcare, Kiryu University, Midori City, Gunma), Nobuo Nishi (Project for the National Health and Nutrition Survey, National Institute of Health and Nutrition, Tokyo), Nagako Okuda (The First Institute for Health Promotion and Health Care, Japan Anti-Tuberculosis Association, Tokyo), Toru Izumi (Faculty of Medicine, Kitasato University, Sagamihara, Kanagawa), Toshiyuki Ojima (Department of Community Health and Preventive Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka), Koji Tamakoshi (Department of Public Health and Health Information Dynamics, Nagoya University Graduate School of Medicine, Nagoya, Aichi), Hideaki Nakagawa (Department of Epidemiology and Public Health, Kanazawa Medical University, Kanazawa, Ishikawa), Katsuyuki Miura, Takayoshi Ohkubo, Yoshikuni Kita, Aya Kadota (Department of Health Science, Shiga University of Medical Science, Otsu, Shiga), Yasuyuki Nakamura (Cardiovascular Epidemiology, Kyoto Women's University, Kyoto), Katsushi Yoshita (Osaka City University Graduate School of human life science, Osaka), Kazunori Kodama, Fumiyoshi Kasagi (Radiation Effects Research Foundation, Hiroshima), and Yutaka Kiyohara (Department of Environmental Medicine, Kyushu University, Fukuoka).

References

[1] Reaven GM. Banting lecture role of insulin resistance in human disease. Diabetes 1988;37:1595–607.
[2] Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989;149:1514–20.
[3] DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173–94.
[4] Fujioka S, Matsuzawa Y, Tokunaga K, et al. Contribution of intra-abdominal visceral fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987;36:54–9.
[5] McNeil AM, Rosamond WD, Girman C, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care 2005;28:385–90.
[6] Katzmarzyk PT, Church TS, Blair SN. Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med 2004;164:1092–7.
[7] Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. A summary of the evidence. Diabetes Care 2005;28:1769–78.
[8] Kadota A, Hozawa A, Okamura T, et al. Relationship between metabolic risk factor clustering and cardiovascular mortality stratified by high blood glucose and obesity: NIPPON DATA90, 1990–2000. Diabetes Care 2007;30:1533–8.
[9] Iso H, Sato S, Kitamura A, et al. Metabolic syndrome and the risk of ischemic heart disease and stroke among Japanese men and women. Stroke 2007;38:1744–51.
[10] Ninomiya T, Kubo M, Doi Y, et al. Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population. The Hisayama Study. Stroke 2007:2063–9.
[11] Kokubo Y, Okamura T, Yoshimasa Y, et al. Impact of metabolic syndrome components of the incidence of cardiovascular disease in a general urban Japanese population: the Suita study. Hypertens Res 2008;31:2027–35.
[12] Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.
[13] Alberti KG, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539–53.
[14] Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006;23:469–80.
[15] The Examination Committee of Criteria for 'Obesity Disease' in Japan, Japan Society for the Study of Obesity. New criteria for 'obesity disease' in Japan. Circ J 2002;66:987–92.
[16] Grundy SM, Cleeman JI, Merz NB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227–39.
[17] Gundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–52.
[18] NIPPON DATA80 Research Group. Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population. Circ J 2006;70:1249–55.
[19] NIPPON DATA80 Research Group. Impact of elevated blood pressure on mortality from all causes, cardiovascular diseases, heart disease and stroke among Japanese: 14 year follow-up of randomly selected population from Japanese—NIPPON DATA80. J Hum Hypertens 2003;17:851–7.
[20] Okamura T, Tanaka H, Miyamatsu N, et al. The relationship between serum total cholesterol and all-cause or cause-specific mortality in a 17.3-year study of a Japanese cohort. Atherosclerosis 2007;190:216–23.
[21] Oki I, Nakamura Y, Okamura T, et al. Body mass index and risk of stroke mortality among a random sample of Japanese adults: 19-year follow-up of NIPPON DATA80. Cerebrovasc Dis 2006;22:404–15.
[22] Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008;359:2105–20.
[23] Okamura T, Hayakawa T, Kadowaki T, et al. Resting heart rate and cause-specific death in a 16.5-year cohort study of the Japanese general population. Am Heart J 2004;147:1024–32.
[24] American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009;29:S43–8.
[25] Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee of Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003;289:2560–72.
[26] Greenland S. Re: Confidence limits made easy: interval estimation using a substitution method. Am J Epidemiol 1999;149:884.
[27] Kannel WB, Vasan RS, Levy D. Is the relation of systolic blood pressure to risk of cardiovascular disease continuous and graded, or are there critical values? Hypertension 2003;42:453–6.
[28] Khaw KT, Wareham N, Bingham S, et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004;141:413–20.
[29] Vasan RS, Sullivan LM, Wilson PWF, et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med 2005;142:393–402.
[30] Khot UN, Khot MB, Bajzaer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290:898–904.
[31] Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003;290:891–7.

CVD Prevention and Control (2010) 5, 97–103

available at www.sciencedirect.com

ScienceDirect

journal homepage: www.elsevierhealth.com/journals/precon

Risk factors for heart failure and coronary heart disease mortality over 24-year follow-up period in Japan: NIPPON DATA80

Yasuyuki Nakamura [a,b,*], Tanvir C. Turin [b], Nahid Rumana [b], Katsuyuki Miura [b], Yoshikuni Kita [b], Naoyuki Takashima [b], Akira Fujiyoshi [b], Takehito Hayakawa [c], Tomonori Okamura [d], Hirotsugu Ueshima [b], for the NIPPON DATA Research Group

[a] *Cardiovascular Epidemiology, Kyoto Women's University, Kyoto, Japan*
[b] *Department of Health Science, Shiga University of Medical Science, Shiga, Japan*
[c] *Department of Hygiene and Preventive Medicine, Fukushima Medical University, Fukushima, Japan*
[d] *Department of Preventive Cardiology, National Cardiovascular Center, Osaka, Japan*

Received 24 April 2010; received in revised form 12 June 2010; accepted 20 June 2010
Available online 5 August 2010

KEYWORDS
Heart failure;
Coronary heart disease;
Mortality;
Cohort study;
Body mass index

Summary
Background: Although prevention of heart failure (HF) is an urgent public health need with national and global implications, population-based studies are rare.
Methods and results: We studied risk factors for HF and coronary heart disease (CHD) mortality using the NIPPON DATA80 database with a 24-year follow-up. At the baseline in 1980, data were collected on study participants aged 30 years and over from randomly selected areas in Japan. We followed 9300 participants (44% men, mean age 51). Over the 24-year follow-up, there were 189 deaths from HF (82 men and 107 women) and 188 (91 men and 97 women) from CHD. Cox analyses revealed common and specific risk factors for both mortalities. Common risk factors were: systolic blood pressure for male HF (hazard ratio: 1.28 per 1SD, $P = 0.02$) and for CHD in both (men: 1.20, $P = 0.01$; women: 1.27, $P = 0.003$), smoking for male CHD (1.31, $P = 0.004$) and for female HF (1.39, $P = 0.01$), blood sugar for HF and CHD in men (HF: 1.21 per 1SD, $P = 0.009$; CHD: 1.29, $P < 0.0001$); T wave abnormality in male HF (2.33, $P = 0.003$) and female CHD (1.84, $P = 0.001$). Specific risk factors were: serum creatinine for HF in both (men: 1.14 per 1SD, $P < 0.0001$, women: 1.09, $P = 0.01$); total cholesterol for CHD in men

* Corresponding author at: Cardiovascular Epidemiology, Kyoto Women's University, 35 Imakumano Kitahiyoshi-cho, Higashiyama-ku, Kyoto 605-8501, Japan. Tel./fax: +81 75 531 2162.
E-mail address: nakamury@kyoto-wu.ac.jp (Y. Nakamura).

1875-4570/$ - see front matter
doi:10.1016/j.cvdpc.2010.06.002

(1.38 per 1SD, $P = 0.001$), history of valvular heart disease (6.48, $P = 0.002$) or stroke (2.41, $P = 0.048$) in male HF, and history of angina in female CHD (3.59, $P = 0.003$).
Conclusion: Common and specific measures need to be undertaken to prevent HF and CHD mortality.

Introduction

Although the incidence and mortality from coronary heart disease (CHD) and stroke have been decreasing in Western industrial countries, the incidence and mortality from heart failure (HF), common pathways from many roots of heart diseases, have been increasing [1,2]. Improved care of acute CHD events and of patients with HF, and aging populations cause these trends [3,4]. Among industrial countries, CHD mortality in Japan has been the lowest and the age-standardized mortality from CHD has been stable for decades [5]. However, crude mortality from CHD and HF has been increasing recently in Japan due to the aging of the population [6,7]. In fact, Japan had the highest proportion of those aged 65 and older in the world in 2005 [8]. In order to prevent HF, the risk factors should be clarified. Most of the knowledge about the risk factors for HF is based on North American and European studies [4,9,11,12]. Since HF is a global burden, studies on the risk factors outside North American and European countries are also needed. For unbiased information on the risk factors for HF, population-based studies are essential; there have been no such studies outside North American and European countries.

In the present study, we examined risk factors for HF and CHD mortality using the NIPPON DATA80 database [9–14] with a 24-year follow-up period.

Methods

Participants

The participants in this cohort were those in the 1980 National Survey on Circulatory Disorders [9]. A total of 10,546 community-based participants aged 30 years and over in 300 randomly selected health districts throughout Japan participated in the survey, which consisted of history-taking, physical examinations, blood tests and a self-administered questionnaire on lifestyle. For the present study, participants were followed up to 2004 (NIPPON DATA80, 1980–2004). The overall population aged 30 years and over in the participating health districts was 13,771. The participation rate was 76.6% (10,546 of 13,771) before exclusion for reasons mentioned below.

We reviewed the residence records of all the study participants for vital status. In fatal cases, the causes were examined. To clarify the cause of death, we used the National Vital Statistics records. The underlying cause of death was coded according to the 9th International Classification of Diseases for the National Vital Statistics until the end of 1994 and according to the 10th International Classification of Diseases from the beginning of 1995. Deaths were confirmed in each district by computer-matching of data from the Vital Statistics records using the district, sex, and dates of birth and death as key codes. Participants were excluded from follow-up because of missing baseline data ($N = 139$), or loss to follow-up ($N = 1105$). The latter group was excluded because of the absence of a permanent address that was needed to link to Vital Statistics records. The final sample comprised 9300 participants (4091 men and 5209 women). There were no significant differences between participants who were lost to follow-up and those who were included in the current study in terms of several risk factors. Therefore, the potential bias regarding the 1105 participants lost to follow-up is thought to be negligible. Permission to use the National Vital Statistics records was obtained from the Management and Coordination Agency, Government of Japan. Ethical approval for this study was obtained from the Institutional Review Board of Shiga University of Medical Science for ethical issues (No. 12-18, 2000).

Biochemical and baseline examinations

The baseline surveys were conducted at public health centers. Blood pressure was measured by trained research nurses using a standard mercury sphygmomanometer on the right arm of seated participants after at least 5 min of rest. Height and weight were measured in stocking feet and light clothing. BMI was calculated as weight (kg) divided by the square of height (m^2).

A lifestyle survey was also carried out using a self-administered questionnaire. Participants were asked about their alcohol drinking habit (never, past, occasional, and daily drinkers). Reported information was confirmed by public health nurses through interviews with the study participants regarding smoking, drinking habit, and present and past medical histories.

Casual blood samples were drawn and centrifuged within 60 min of collection and stored at −70 °C until analyses. Serum total cholesterol and creatinine were analyzed in a sequential auto-analyzer (SMA12/60; Technicon, Tarrytown, USA) at a single laboratory (Osaka Medical Center for Health Science and Promotion), a member of the Cholesterol Reference Method Laboratory Network (CRMLN) [10]. Serum concentrations of glucose were measured by the cupric-neocuproline method, and the value was converted so as to better correspond with the more widely used hexokinase method [11].

The ECG findings were independently evaluated by two trained researchers in each of 12 institutions according to the Minnesota Code (mc) as previously described [12]. Major ECG findings were tall R (mc3-1 to 3-4), ST depression (mc4-1 to 4-4) and T abnormality (mc5-1 to 5-5).

Statistical analysis

SAS version 9.1 for Windows (SAS Institute, Cary, NC) was used throughout the analyses. The chi-square test was used

to compare dichotomous variables, followed by a *post hoc* application of Bonferroni's method. A one-way analysis of variance was used to compare means among the three groups stratified by outcome, followed by a *post hoc* application of Dunnett's test when the F value showed a significant difference at $P < 0.05$. To examine the factors associated with HF and CHD mortality, multivariate-adjusted hazard ratios were calculated using a Cox proportional hazards model. Men and women were analyzed separately. Age, BMI (<18.5 or ⩾25 vs 18.5–25 kg/m^2), systolic BP, cigarette smoking (never and past smokers, current smokers <20 cigarettes/day, current smokers 20–40 cigarettes/day, and current smokers ⩾41 cigarettes/day), alcohol drinking (ex-drinker or current drinker [occasional drinker or daily drinker] vs never-drinker), self-reported history of valvular heart diseases, stroke, angina; serum total cholesterol, blood glucose and serum creatinine concentrations (model 1). The above continuous variables except for age were standardized to have the mean = 0 and standard deviation = 1. For model 2, ECG findings of T wave abnormality, tall R plus ST depression or T abnormality were separately added to model 1. Since there was a temporary sharp decline in mortality from heart diseases in 1995 due to the 10th International Classification of Diseases regarding the description of diagnosis on death certificates, the above analyses were repeated after dividing the follow-up period into the former and the latter halves (–1994, 1995–).

Results

Baseline characteristics according to outcome in men and women

The baseline characteristics in 4091 men according to outcome over the 24 year follow-up are shown in Table 1. There were 84 deaths from HF and 87 from CHD. The mean age, systolic BP and blood glucose concentration were higher in both mortality groups compared to those in the no HF no CHD mortality control group. Current drinkers were less frequent in both mortality groups compared to those in the control group. Those with T abnormality, and those with tall R wave + ST depression or T abnormality were more frequent in both mortality groups compared to those in the control group. The mean diastolic BP and total cholesterol were higher in the CHD mortality group than those in the controls. Those with BMI < 18.5 kg/m^2, a history of valvular heart disease or stroke were more frequent in the HF mortality groups compared to those in the control group.

The baseline characteristics in 5209 women according to outcome over the 24 year follow-up are shown in Table 2. There were 100 deaths from HF and 88 from CHD. The mean age, systolic and diastolic BP, total cholesterol, blood glucose and creatinine concentrations were higher in both mortality groups compared to those in the control group. Those with BMI < 18.5 kg/m^2 were more frequent in the HF mortality group compared to those in the control group. Current drinkers were less frequent in the HF mortality group and current smokers were more frequent in the CHD mortality group than those in the control group. Those with T abnormality, and those with tall R wave + ST depression or T abnormality were more frequent in both mortality groups compared to those in the control group. Those with a history of stroke were more frequent in both mortality groups compared to those in the control group. Those with a history of angina were more frequent in the CHD mortality group than those in the control group.

Factors associated with HF and CHD mortality

The Cox multivariate hazard ratios for HF and CHD mortality in 4091 men are shown in Table 3. Older age, systolic BP, and blood glucose concentration were significantly associated with a higher mortality from HF and CHD. A higher creatinine concentration, history of valvular heart diseases or stroke, and presence of T wave abnormality were associated with a higher HF mortality. Smoking and a higher total cholesterol concentration were associated with a higher CHD mortality.

The results for 5209 women are shown in Table 4. Among continuous variables, only older age was significantly associated with a higher mortality from HF and CHD. A higher systolic BP and history of angina were associated with a higher CHD mortality, while higher creatinine was associated with a higher HF mortality. Smoking was associated with HF mortality. Both ECG abnormalities were associated with a higher CHD mortality.

Secondary analyses after dividing the follow-up period into the former and latter halves yielded similar results except for reduced statistical significance due to a loss of statistical power.

Discussion

Most of the risk factors for HF mortality found in the present study, such as older age, BP, blood glucose and history of valvular heart disease are compatible with previous studies in the US and Europe [2,4,13–15]. The higher serum creatinine found in the present study has also been reported [13].

In the present study, BMI < 18.5 kg/m^2 was associated with a significant increase in HF mortality in men and women. Although statistically insignificant, BMI ⩾ 25.0 kg/m^2 in men tended to be associated with a lower HF mortality in our study. Obesity has been demonstrated in general populations to predispose people to HF [4,14]. Obesity contributes to atherogenic risk factors through neurohormonal regulation. Obesity also increases preload and afterload, which predispose to HF. However, a number of recent large-scale clinical studies in patients with established heart failure have shown that being underweight or having low BMI was associated with increased mortality, while elevated BMI is associated with a better prognosis [14,15]. Kistorp et al. found lower adiponectin concentrations, that occur in the setting of increased BMI, were associated with improved survival in patients with compensated HF [16]. Furthermore, in other chronic impaired health conditions such as chronic obstructive pulmonary disease, cancer, renal failure, or liver cirrhosis, obese patients show better survival [17]. Possible misdiagnosis of HF in obese people cannot account for all these findings. Because obese people have more adipose tissue, they have more reserves and can survive longer. Another potential explanation is the presence of cardiac cachexia in patients with advanced HF

Table 1 Baseline characteristics according to outcome over a 24 year follow-up in 4091 men — NIPPON DATA80, 1980–2004.

	No HF–CHD	HF death	CHD death	*P*
N (subtotal 4091)	3918	82	91	
Age (year)	50.2 ± 13.0	67.3 ± 11.0**	61.7 ± 11.0**	<0.0001
BMI (kg/m^2)	22.5 ± 2.9	21.4 ± 2.8**	22.9 ± 3.0	0.0007
BMI < 18.5 kg/m^2 (%)	6.3	15.9**	7.7	0.002
BMI ⩾ 25.0 kg/m^2 (%)	19.2	9.8	20.9	0.09
SBP (mmHg)	138 ± 21	153 ± 24**	150 ± 22**	<0.0001
DBP (mmHg)	84 ± 12	84 ± 11	87 ± 14*	0.04
Smoking (%)	62.9	59.8	62.6	0.84
Drinking (%)	75.0	52.4**	60.4**	<0.0001
Valve HD (%)	0.5	3.7*	1.1	0.0006
Hx of stroke	1.6	7.3**	1.1	0.0004
Hx of angina	1.1	0	2.2	0.39
Hx of AMI	0.5	0	0	0.67
TCH (mg/dl)	186 ± 33	182 ± 29	197 ± 36**	0.004
Blood glucose (mg/dl)	102 ± 31	116 ± 33**	121 ± 60**	<0.0001
Creatinine (mg/dl)	1.05 ± 0.19	1.22 ± 1.06**	1.11 ± 0.24	<0.0001
T abnormality (%)	5.9	23.2**	15.4**	<0.0001
Tall R + (ST depr or T abn) (%)	2.7	11.2*	13.4*	<0.0001

HF = heart failure, CHD = coronary heart disease, No HF–CHD = no HF and no CHD mortality control group, BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, valve HD = history of valvular heart disease, TCH = serum total cholesterol concentration, tall R = tall R wave on ECG, ST depr = ST depression, T abn = T abnormality.
* $P < 0.05$: no HF–CHD group vs HF death or CHD death group.
** $P < 0.01$: no HF–CHD group vs HF death or CHD death group.

Table 2 Baseline characteristics according to outcome over 24 year follow-up in 5209 women — NIPPON DATA80, 1980–2004.

	No HF–CHD	HF death	CHD death	*P*
N (subtotal 5209)	5005	107	97	
Age (year)	50.3 ± 13.0	69.8 ± 9.0**	67.1 ± 9.2**	<0.0001
BMI (kg/m^2)	22.9 ± 3.4	22.5 ± 4.0	22.9 ± 3.7	0.56
BMI < 18.5 kg/m^2 (%)	6.9	15.0**	10.3	0.003
BMI ⩾ 25.0 kg/m^2 (%)	22.9	23.4	23.7	0.97
SBP (mmHg)	133 ± 21	151 ± 25**	151 ± 23**	<0.0001
DBP (mmHg)	79 ± 12	84 ± 13**	85 ± 13**	<0.0001
Smoking (%)	8.7	13.1	15.5*	0.01
Drinking (%)	20.0	7.5**	20.6	0.006
Valve HD (%)	0.6	1.9	1.0	0.27
Hx of stroke	0.6	2.8**	3.1**	0.0007
Hx of angina	1.0	1.9	6.2**	<0.0001
Hx of AMI	0.5	0	0	0.59
TCH (mg/dl)	191 ± 34	202 ± 34**	205 ± 41**	<0.0001
Blood glucose (mg/dl)	100 ± 28	109 ± 39**	114 ± 37**	<0.0001
Creatinine (mg/dl)	0.84 ± 0.15	0.95 ± 0.24**	0.91 ± 0.24**	<0.0001
T abnormality (%)	10.2	26.2**	29.9**	<0.0001
Tall R + (ST depr or T abn) (%)	3.8	9.8**	9.9**	0.0004

HF = heart failure, CHD = coronary heart disease, No HF–CHD = no HF and no CHD mortality control group, BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, valve HD = history of valvular heart disease, TCH = serum total cholesterol concentration, tall R = tall R wave on ECG, ST depr = ST depression, T abn = T abnormality.
* $P < 0.05$: no HF–CHD group vs HF death or CHD death group.
** $P < 0.01$: no HF–CHD group vs HF death or CHD death group.

[14]. Basically, the results of our study in a relatively less obese population are consistent with those of previous studies [14,15].

History of stroke in men was one of the risk factors for HF mortality in our study. Although it has not been identified as a risk factor for HF incidence or mortality in previous studies, He et al. showed physical inactivity was an important risk factor for developing HF [18]. As we did not have any quantitative data on physical activity, history of stroke may have reflected physical inactivity.

Table 3 Cox multivariate hazard ratios for heart failure and coronary heart disease mortality in 4091 men — NIPPON DATA80, 1980–2004.

	HF death	*P*	CHD death	*P*
Model 1				
Age	**1.14 (1.11–1.17)**	**<0.0001**	**1.10 (1.08–1.13)**	**<0.0001**
BMI < 18.5 kg/m^2	**1.92 (1.04–3.55)**	**0.04**	1.25 (0.56–2.76)	0.59
BMI ⩾ 25.0 kg/m^2	0.69 (0.33–1.46)	0.71	1.09 (0.63–1.87)	0.76
SBP†	**1.28 (1.04–1.58)**	**0.02**	**1.29 (1.05–1.58)**	**0.01**
Smoking	1.16 (0.92–1.47)	0.21	**1.31 (1.09–1.58)**	**0.004**
Drinking	0.66 (0.40–1.09)	0.11	0.66 (0.41–1.05)	0.08
Valve HD	**6.48 (1.99–21.2)**	**0.002**	1.79 (0.25–13.1)	0.56
Hx of stroke	**2.41 (1.01–5.78)**	**0.048**	0.44 (0.06–3.24)	0.42
Hx of angina	0.00 (0.00–)	0.98	1.23 (0.30–5.06)	0.77
TCH†	0.97 (0.77–1.23)	0.83	**1.38 (1.14–1.67)**	**0.001**
Blood glucose†	**1.21 (1.05–1.39)**	**0.009**	**1.29 (1.17–1.41)**	**<0.0001**
Creatinine†	**1.14 (1.08–1.20)**	**<0.0001**	1.08 (0.96–1.22)	0.20
Model 2 (ECG findings)				
T abnormality	**2.33 (1.33–4.08)**	**0.003**	1.53 (0.84–2.82)	0.16
Tall R + (ST depr or T abn)	1.37 (0.63–2.97)	0.43	1.66 (0.79–3.46)	0.18

Variables with † were standardized to have mean = 0, standard deviation = 1. Model 1 covariates included age, BMI (<18.5 or ⩾25 vs 18.5–25 kg/m^2), SBP, smoking (never and past smokers, current smokers <20 cigarettes/day, current smokers 20–40 cigarettes/day, and current smokers ⩾41 cigarettes/day), alcohol drinking (ex-drinker or current drinker [occasional drinker or daily drinker] vs never-drinker), self-reported history of valve HD, stroke, angina; serum TCH, blood glucose and serum creatinine concentrations. For model 2, ECG findings of T wave abnormality, or tall R plus ST depression or T abnormality were separately added to model 1. HF = heart failure, CHD = coronary heart disease, no HF–CHD = no HF and no CHD mortality control group, BMI = body mass index, SBP = systolic blood pressure, valve HD = history of valvular heart disease, TCH = serum total cholesterol concentration, tall R = tall R wave on ECG, ST depr = ST depression, T abn = T abnormality.

Table 4 Cox multivariate hazard ratios for heart failure and coronary heart disease mortality in 5209 women — NIPPON DATA80, 1980–2004.

	HF death	*P*	CHD death	*P*
Model 1				
Age	**1.17 (1.15–1.20)**	**<0.0001**	**1.15 (1.12–1.17)**	**<0.0001**
BMI < 18.5 kg/m^2	**1.86 (1.04–3.30)**	**0.04**	1.67 (0.83–3.36)	0.15
BMI ⩾ 25.0 kg/m^2	0.98 (0.61–1.56)	0.92	0.95 (0.57–1.58)	0.83
SBP†	1.20 (0.99–1.45)	0.07	**1.27 (1.04–1.56)**	**0.003**
Smoking	**1.39 (1.07–1.81)**	**0.01**	1.35 (0.97–1.89)	0.10
Drinking	**0.44 (0.23–0.98)**	**0.04**	1.49 (0.90–2.46)	0.12
Valve HD	2.14 (0.52–8.74)	0.29	1.09 (0.15–7.88)	0.93
Hx of stroke	1.74 (0.54–5.56)	0.30	1.62 (0.50–5.27)	0.43
Hx of angina	0.91 (0.22–3.73)	0.90	**3.59 (1.53–8.38)**	**0.003**
TCH†	1.01 (0.82–1.24)	0.87	1.09 (0.88–1.35)	0.43
Blood glucose†	1.09 (0.92–1.29)	0.34	**1.15 (1.04–1.37)**	**0.02**
Creatinine†	**1.09 (1.02–1.16)**	**0.01**	1.05 (0.94–1.17)	0.36
Model 2 (ECG findings)				
T abnormality	1.39 (0.89–2.18)	0.14	**1.84 (1.16–2.85)**	**0.01**
Tall R + (ST depr or T abn)	1.65 (0.89–3.07)	0.11	**2.46 (1.34–4.51)**	**0.004**

Variables with † were standardized to have mean = 0, standard deviation = 1. Covariates included in models 1 and 2 were the same as Table 3. HF = heart failure, CHD = coronary heart disease, no HF–CHD = no HF and no CHD mortality control group, BMI = body mass index, SBP = systolic blood pressure, valve HD = history of valvular heart disease, TCH = serum total cholesterol concentration, tall R = tall R wave on ECG, ST depr = ST depression, T abn = T abnormality.

T wave abnormality in men in our study was associated with about a 2.4-fold increase in HF mortality, consistent with previous studies [19,20]. Although the prevalence of current smokers and drinkers in women was lower compared to men, both of them were associated with significant differences in HF mortality, the former with an increase and the latter with a decrease. These results are consistent with previous studies. The reason why these risk factors were not associated with significant changes in HF mortality in men may be due to the fact that there were relatively fewer non-smokers and non-drinkers among the men to serve as references.

Gender specific differences in risk factors for HF or CHD mortality are worth mentioning. Although total cholesterol in men was a significant risk factor for CHD mortality, it was not in women. History of angina in women was a significant risk factor for CHD mortality, it was not in women. In Japan as in rest of the world, CHD mortality is far less in women than in men. Thus, some risk factors, such as a higher total cholesterol might not have been shown as a risk factor due to lack of statistical power. However, history of angina in women was shown as a significant risk factor, while in men there was not even a trace of a trend. It may be related that the syndrome of angina-like chest pain with normal epicardial artery is more common in women than in men [21]. Women with chest pain might have been paid less medical attention than men. The present finding that valvular heart disease in men was a significant risk factor for HF mortality, but not in women, may be related to the fact that valvular aortic stenosis, which has more prognostic significance than the other valvular heart diseases, is more common in men than in women [22].

Strengths and limitations of the study

The strengths of our study include its prospective design and the follow-up of a randomly selected sample from the general population of Japan with a high response rate (76.3%). Since the study included men and women with a broad range of ages, findings are likely to be generalizable to middle-aged and elderly Japanese.

As in any long-term follow-up study, however, there are some weaknesses. We used mortality data as end points, which can lead to misclassification of the cause of death. It has also been reported that most cases of sudden cardiac death tend to be described on Japanese death certificates as "CHD", "HF" or "unknown cause" [21]. Furthermore, mortality statistics for CHD may have been underestimated up to the end of 1994 using ICD9, since deaths from coronary events may have been miscoded as "HF" [23]. However, comparing risk factors for HF and CHD mortality presented in Tables 3 and 4, there were specific risk factors for each of the mortalities, such as history of valvular heart disease in male HF, a higher total cholesterol concentration in male CHD, and history of angina in female CHD mortality. Furthermore, secondary analyses after dividing the follow-up period into the former and latter halves yielded similar results, except for reduced statistical significance due to a loss of statistical power, indicating that our mortality data were reliable despite a few possible misclassifications. Furthermore, recent advances in medical treatment for modifiable risk factors such as hypertension, hypercholesterolemia, or glucose intolerance might have diluted the detrimental effects of risk factors for HF and CHF mortality.

Acknowledgments

The authors thank all members of the Japanese Association of Public Health Center Directors and all staff of the public health centers that cooperated with our study. Investigators and members of the research group are listed in the appendix of Reference [12].

Funding sources

This study was supported by a grant-in-aid of the Ministry of Health and Welfare under the auspices of the Japanese Association for Cerebro-cardiovascular Disease Control, the Research Grant for Cardiovascular Diseases (7A-2) from the Ministry of Health, Labor and Welfare and a Health and Labor Sciences Research Grant, Japan (Comprehensive Research on Aging and Health: H11-Chouju-046, H14-Chouju-003, H17-Chouju-012, H19-Chouju-014), and by the Japan Society for the Promotion of Science invitation fellowship programs for research in Japan. Tanvir Chowdhury Turin and Nahid Rumana are supported by the fellowship from the Japan Society for the Promotion of Science (JSPS).

Disclosures

We have no conflicts of interest to disclose.

References

[1] Kannel WB, D'Agostino RB, Silbershatz H, Belanger AJ, Wilson PW, Levy D. Profile for estimating risk of heart failure. Arch Intern Med 1999;159:1197–204.

[2] Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2008;117:2544–65.

[3] Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397–402.

[4] Kenchaiah S, Narula J, Vasan RS. Risk factors for heart failure. Med Clin North Am 2004;88:1145–72.

[5] Uemura K. World health situation and trend assessment from 1948 to 1988. Bull World Health Organ 1988;66:679–87.

[6] Kitamura A, Iso H, Iida M, Naito Y, Sato S, Jacobs DR, et al. Trends in the incidence of coronary heart disease and stroke and the prevalence of cardiovascular risk factors among Japanese men from 1963 to 1994. Am J Med 2002;112:104–9.

[7] Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, et al. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 2003;34:2349–54.

[8] The 2005 population census. <http://www.stat.go.jp/english/data/kokusei/2005/youkei/01.htm>; 2005.

[9] Okamura T, Kadowaki T, Hayakawa T, Kita Y, Okayama A, Ueshima H. What cause of mortality can we predict by cholesterol screening in the Japanese general population? J Intern Med 2003;253:169–80.

[10] Nakamura M, Sato S, Shimamoto T. Improvement in Japanese clinical laboratory measurements of total cholesterol and HDL-cholesterol by the US Cholesterol Reference Method Laboratory Network. J Atheroscler Thromb 2003;10:145–53.
[11] Iso H, Imano H, Kitamura A, Sato S, Naito Y, Tanigawa T, et al. Type 2 diabetes and risk of non-embolic ischaemic stroke in Japanese men and women. Diabetologia 2004;47:2137–44.
[12] Horibe H, Kasagi F, Kagaya M, Matsutani Y, Okayama A, Ueshima H. A nineteen-year cohort study on the relationship of electrocardiographic findings to all cause mortality among subjects in the national survey on circulatory disorders, NIPPON DATA80. J Epidemiol 2005;15:125–34.
[13] Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681–9.
[14] Curtis JP, Selter JG, Wang Y, Rathore SS, Jovin IS, Jadbabaie F, et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med 2005;165:55–61.
[15] Kenchaiah S, Pocock SJ, Wang D, Finn PV, Zornoff LA, Skali H, et al. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2007;116:627–36.
[16] Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756–62.
[17] Springer J, von Haehling S, Anker SD. The need for a standardized definition for cachexia in chronic illness. Nat Clin Pract Endocrinol Metab 2006;2:416–7.
[18] He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001;161:996–1002.
[19] Okin PM, Devereux RB, Nieminen MS, Jern S, Oikarinen L, Viitasalo M, et al. Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. Circulation 2006;113:67–73.
[20] Rautaharju PM, Kooperberg C, Larson JC, LaCroix A. Electrocardiographic predictors of incident congestive heart failure and all-cause mortality in postmenopausal women: the Women's Health Initiative. Circulation 2006;113:481–9.
[21] Cannon III RO. Chest pain and the sensitive heart. Eur J Gastroenterol Hepatol 1995;7:1161–71.
[22] Carabello BA. Clinical practice. Aortic stenosis. N Engl J Med 2002;346:677–82.
[23] Saito I, Folsom AR, Aono H, Ozawa H, Ikebe T, Yamashita T. Comparison of fatal coronary heart disease occurrence based on population surveys in Japan and the USA. Int J Epidemiol 2000;29:837–44.